JNTU Pharm. D III Year MEDICINAL CHEMISTRY Previous Question Paper (October/November - 2019 - R08)

Hansch analysis is a quantitative structure-activity relationship (QSAR) approach that correlates the biological activity of a series of compounds with their physicochemical properties. It utilizes a mathematical model, typically a linear regression equation, to relate biological activity (expressed as log 1/C) to parameters representing lipophilicity (log P), electronic effects (Hammett constant, σ), and steric effects (Taft constant, Es).

The merits of Hansch analysis include:

• It provides a quantitative and predictive framework for drug design, allowing researchers to estimate the activity of untested analogs.
• It enables the simultaneous evaluation of multiple physicochemical parameters, helping to identify which properties are most critical for binding or potency.
• It helps in optimizing lead compounds by identifying the ideal balance of lipophilicity and electronic character required for optimal pharmacological effect.
• It reduces the number of compounds that need to be synthesized and tested, thereby saving time and resources in the drug discovery process.

Computer-Aided Drug Design (CADD) is a specialized discipline that uses computational methods and software to discover, develop, and analyze drugs and related biologically active molecules. It integrates techniques such as molecular modeling, molecular docking, and pharmacophore mapping to simulate the interactions between a drug molecule and its biological target at the atomic level.

The importance of CADD includes:

• Efficiency: It significantly accelerates the drug discovery pipeline by narrowing down the vast chemical space to a smaller set of promising candidates.
• Cost-effectiveness: By predicting binding affinities and ADME properties in silico, it reduces the high costs associated with the synthesis and laboratory testing of inactive or toxic compounds.
• Mechanism Elucidation: It provides deep insights into the structural basis of drug-receptor interactions, facilitating the rational design of more potent and selective inhibitors.
• Lead Optimization: It allows for the virtual modification of chemical structures to improve pharmacokinetic profiles and reduce off-target effects before moving to wet-lab synthesis.